Research graph
References from Associations of cardiometabolic burden with cardiovascular disease–death transitions in metabolic dysfunction-associated steatotic liver disease: a prospective cohort study using multistate analysis. Local targets link to admitted publications; unresolved targets remain external evidence.
MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease
10.1053/j.gastro.2019.11.312 · 2020 · External reference
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
10.1016/j.jhep.2023.06.003 · 2023 · External reference
Current status and future trends of the global burden of MASLD
10.1016/j.tem.2024.02.007 · 2024 · External reference
Systemic metabolic abnormalities: key drivers of complications and mortality in MASLD
10.1016/j.jhep.2024.02.001 · 2024 · External reference
MASLD/MetALD and mortality in individuals with any cardio-metabolic risk factor: a population-based study with 26.7 years of follow-up
10.1097/hep.0000000000000925 · 2025 · External reference
The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis
10.1016/j.jacc.2010.05.034 · 2010 · External reference
Changes of metabolic syndrome status alter the risks of cardiovascular diseases, stroke and all cause mortality
10.1038/s41598-025-86385-1 · 2025 · External reference
Cardiovascular risk from metabolic dysfunction-associated Steatotic liver disease, Cardiometabolic risk factor count, and their longitudinal changes: a Nationwide cohort study
10.14309/ajg.0000000000003274 · 2025 · External reference
Cardiometabolic dysfunction burden and mortality outcomes in metabolic dysfunction-associated steatotic liver disease
10.1371/journal.pone.0327772 · 2025 · External reference
Impact of metabolic dysfunction severity in steatotic liver disease and its interaction with liver fibrosis on all-cause mortality and multiple hepatic and extra-hepatic outcomes
10.1016/j.metabol.2025.156306 · 2025 · External reference
Differential effects of cardiometabolic risk factors on all-cause mortality in United States adults with metabolic dysfunction-associated steatotic liver disease (MASLD)
10.1016/j.cgh.2025.09.003 · 2025 · External reference
UK biobank: opportunities for cardiovascular research
10.1093/eurheartj/ehx254 · 2019 · External reference
UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age
10.1371/journal.pmed.1001779 · 2015 · External reference
Non-alcoholic fatty liver is associated with increased risk of irritable bowel syndrome: a prospective cohort study
10.1186/s12916-022-02460-8 · 2022 · External reference
Role of fatty liver index in risk-stratifying comorbid disease outcomes in non-alcoholic fatty liver disease
10.1016/j.jhepr.2023.100896 · 2023 · External reference
Agreement between the prevalence of nonalcoholic fatty liver disease determined by transient Elastography and fatty liver indices
10.1016/j.cgh.2020.11.028 · 2022 · External reference
Long-term prognosis of lean MASLD: evidence from three population-based prospective cohorts
10.1136/gutjnl-2025-336127 · 2026 · External reference
Binge-pattern alcohol consumption and genetic risk as determinants of alcohol-related liver disease
10.1038/s41467-023-43064-x · 2023 · External reference
Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma
10.1158/1078-0432.ccr-14-0442 · 2014 · External reference
Association between inflammatory burden index and prognosis in patients with coronary heart disease: a retrospective study
10.1371/journal.pone.0325287 · 2025 · External reference
Neutrophil to lymphocyte ratio in relation to risk of all-cause mortality and cardiovascular events among patients undergoing angiography or cardiac revascularization: a meta-analysis of observational studies
10.1016/j.atherosclerosis.2014.03.003 · 2014 · External reference
Characterization of brain morphology associated with metabolic dysfunction-associated steatotic liver disease in the UK biobank
10.1111/dom.16362 · 2025 · External reference
Interleukin-6 induces cellular insulin resistance in hepatocytes
10.2337/diabetes.51.12.3391 · 2002 · External reference
Interleukin-6 attenuates insulin-mediated increases in endothelial cell signaling but augments skeletal muscle insulin action via differential effects on tumor necrosis factor-alpha expression
10.2337/db08-0775 · 2009 · External reference
Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis
10.1002/hep.24001 · 2010 · External reference
Endothelial cell dysfunction and nonalcoholic fatty liver disease (NAFLD): a concise review
10.3390/cells11162511 · 2022 · External reference
Non alcoholic fatty liver disease and eNOS dysfunction in humans
10.1186/s12876-017-0592-y · 2017 · External reference
NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications
10.1136/gutjnl-2020-320622 · 2020 · External reference
Clinical dyslipidaemia is associated with changes in the lipid composition and inflammatory properties of apolipoprotein-B-containing lipoproteins from women with type 2 diabetes
10.1007/s00125-011-2444-6 · 2012 · External reference
Metabolic dysfunction-associated steatotic liver disease in adults
10.1038/s41572-025-00599-1 · 2025 · External reference
Proteomic resolution of the MASLD cardiometabolic spectrum identifies sex-driven endotypes and predicts systemic mortality
10.1136/gutjnl-2026-338674 · 2026 · External reference
Association between mental health and MASLD molecular insights through metabolomics
10.1038/s43856-025-01317-4 · 2025 · External reference
Cigarette smoke contributes to the progression of MASLD: from the molecular mechanisms to therapy
10.3390/cells14030221 · 2025 · External reference
Does moderate alcohol consumption accelerate the progression of liver disease in NAFLD? A systematic review and narrative synthesis
10.1136/bmjopen-2021-049767 · 2022 · External reference
Age-dependent association between modifiable risk factors and incident cardiovascular disease
10.1161/jaha.122.027684 · 2023 · External reference
The association between frailty, the metabolic syndrome, and mortality over the lifespan
10.1007/s11357-017-9967-9 · 2017 · External reference
Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis
10.1002/hep.24001 · ExternalCitation · doi-reference
Clinical dyslipidaemia is associated with changes in the lipid composition and inflammatory properties of apolipoprotein-B-containing lipoproteins from women with type 2 diabetes
10.1007/s00125-011-2444-6 · ExternalCitation · doi-reference
The association between frailty, the metabolic syndrome, and mortality over the lifespan
10.1007/s11357-017-9967-9 · ExternalCitation · doi-reference
Neutrophil to lymphocyte ratio in relation to risk of all-cause mortality and cardiovascular events among patients undergoing angiography or cardiac revascularization: a meta-analysis of observational studies
10.1016/j.atherosclerosis.2014.03.003 · ExternalCitation · doi-reference
Agreement between the prevalence of nonalcoholic fatty liver disease determined by transient Elastography and fatty liver indices
10.1016/j.cgh.2020.11.028 · ExternalCitation · doi-reference
Differential effects of cardiometabolic risk factors on all-cause mortality in United States adults with metabolic dysfunction-associated steatotic liver disease (MASLD)
10.1016/j.cgh.2025.09.003 · ExternalCitation · doi-reference
The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis
10.1016/j.jacc.2010.05.034 · ExternalCitation · doi-reference
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
10.1016/j.jhep.2023.06.003 · ExternalCitation · doi-reference
Systemic metabolic abnormalities: key drivers of complications and mortality in MASLD
10.1016/j.jhep.2024.02.001 · ExternalCitation · doi-reference
Role of fatty liver index in risk-stratifying comorbid disease outcomes in non-alcoholic fatty liver disease
10.1016/j.jhepr.2023.100896 · ExternalCitation · doi-reference
Impact of metabolic dysfunction severity in steatotic liver disease and its interaction with liver fibrosis on all-cause mortality and multiple hepatic and extra-hepatic outcomes
10.1016/j.metabol.2025.156306 · ExternalCitation · doi-reference
Current status and future trends of the global burden of MASLD
10.1016/j.tem.2024.02.007 · ExternalCitation · doi-reference
Binge-pattern alcohol consumption and genetic risk as determinants of alcohol-related liver disease
10.1038/s41467-023-43064-x · ExternalCitation · doi-reference
Metabolic dysfunction-associated steatotic liver disease in adults
10.1038/s41572-025-00599-1 · ExternalCitation · doi-reference
Changes of metabolic syndrome status alter the risks of cardiovascular diseases, stroke and all cause mortality
10.1038/s41598-025-86385-1 · ExternalCitation · doi-reference
Association between mental health and MASLD molecular insights through metabolomics
10.1038/s43856-025-01317-4 · ExternalCitation · doi-reference
MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease
10.1053/j.gastro.2019.11.312 · ExternalCitation · doi-reference
UK biobank: opportunities for cardiovascular research
10.1093/eurheartj/ehx254 · ExternalCitation · doi-reference
MASLD/MetALD and mortality in individuals with any cardio-metabolic risk factor: a population-based study with 26.7 years of follow-up
10.1097/hep.0000000000000925 · ExternalCitation · doi-reference
Characterization of brain morphology associated with metabolic dysfunction-associated steatotic liver disease in the UK biobank
10.1111/dom.16362 · ExternalCitation · doi-reference
Does moderate alcohol consumption accelerate the progression of liver disease in NAFLD? A systematic review and narrative synthesis
10.1136/bmjopen-2021-049767 · ExternalCitation · doi-reference
NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications
10.1136/gutjnl-2020-320622 · ExternalCitation · doi-reference
Long-term prognosis of lean MASLD: evidence from three population-based prospective cohorts
10.1136/gutjnl-2025-336127 · ExternalCitation · doi-reference
Proteomic resolution of the MASLD cardiometabolic spectrum identifies sex-driven endotypes and predicts systemic mortality
10.1136/gutjnl-2026-338674 · ExternalCitation · doi-reference
Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma
10.1158/1078-0432.ccr-14-0442 · ExternalCitation · doi-reference
Age-dependent association between modifiable risk factors and incident cardiovascular disease
10.1161/jaha.122.027684 · ExternalCitation · doi-reference
Non alcoholic fatty liver disease and eNOS dysfunction in humans
10.1186/s12876-017-0592-y · ExternalCitation · doi-reference
Non-alcoholic fatty liver is associated with increased risk of irritable bowel syndrome: a prospective cohort study
10.1186/s12916-022-02460-8 · ExternalCitation · doi-reference
UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age
10.1371/journal.pmed.1001779 · ExternalCitation · doi-reference
Association between inflammatory burden index and prognosis in patients with coronary heart disease: a retrospective study
10.1371/journal.pone.0325287 · ExternalCitation · doi-reference
Cardiometabolic dysfunction burden and mortality outcomes in metabolic dysfunction-associated steatotic liver disease
10.1371/journal.pone.0327772 · ExternalCitation · doi-reference
Cardiovascular risk from metabolic dysfunction-associated Steatotic liver disease, Cardiometabolic risk factor count, and their longitudinal changes: a Nationwide cohort study
10.14309/ajg.0000000000003274 · ExternalCitation · doi-reference
Interleukin-6 attenuates insulin-mediated increases in endothelial cell signaling but augments skeletal muscle insulin action via differential effects on tumor necrosis factor-alpha expression
10.2337/db08-0775 · ExternalCitation · doi-reference
Interleukin-6 induces cellular insulin resistance in hepatocytes
10.2337/diabetes.51.12.3391 · ExternalCitation · doi-reference
Endothelial cell dysfunction and nonalcoholic fatty liver disease (NAFLD): a concise review
10.3390/cells11162511 · ExternalCitation · doi-reference
Cigarette smoke contributes to the progression of MASLD: from the molecular mechanisms to therapy
10.3390/cells14030221 · ExternalCitation · doi-reference
